These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 21649882)

  • 21. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
    Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
    Jang SM; Lewis SJ; Rhie SJ
    J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients.
    Schießer S; Hitzenbichler F; Kees MG; Kratzer A; Lubnow M; Salzberger B; Kees F; Dorn C
    Ther Drug Monit; 2021 Apr; 43(2):264-270. PubMed ID: 33086362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
    Cotner SE; Rutter WC; Burgess DR; Wallace KL; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous infusion beta-lactams for intensive care unit pulmonary infections.
    Frei CR; Burgess DS
    Clin Microbiol Infect; 2005 May; 11(5):418-21. PubMed ID: 15819874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
    Mefford B; Wallace KL; Donaldson JC; Bissell Turpin BD; Sen P; Schadler AD; Liu LJ; Thompson Bastin ML
    Antimicrob Agents Chemother; 2024 May; 68(5):e0108523. PubMed ID: 38606975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
    Bauer SR; Salem C; Connor MJ; Groszek J; Taylor ME; Wei P; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
    Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study.
    Kühn D; Metz C; Seiler F; Wehrfritz H; Roth S; Alqudrah M; Becker A; Bracht H; Wagenpfeil S; Hoffmann M; Bals R; Hübner U; Geisel J; Lepper PM; Becker SL
    Crit Care; 2020 Nov; 24(1):664. PubMed ID: 33239110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance.
    Jacobs A; Taccone FS; Roberts JA; Jacobs F; Cotton F; Wolff F; Creteur J; Vincent JL; Hites M
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.